SOHM said that the branded products, many of the first-line therapies, will lose patent protection over the next 5 years in the US and present significant opportunities for product line expansion and over 49 such products will be affected by the end of 2013, including Topamax, Effexor XR, Lipitor, Plavix and Cymbalta.
SOHM expects to continue expansion of its product lines and strengthen market penetration and revenue growth in key emerging markets including India, Africa, Latin America and Southeast Asia.
SOHM Corporate Strategy vice president Shailesh Shah said that branded generics represent the growth opportunity in emerging markets for pharmaceutical sales.
"These target markets offer the highest global growth rates, continue to be very profitable and are largely underrepresented by large drug companies. We see huge potential for increased revenue and sales growth of the SOHM brand," Shah said.